Generali Investments Management Co LLC Acquires New Position in Insulet Corporation $PODD

Generali Investments Management Co LLC acquired a new stake in Insulet Corporation (NASDAQ:PODD) in the 2nd quarter, HoldingsChannel.com reports. The institutional investor acquired 175 shares of the medical instruments supplier’s stock, valued at approximately $55,000.

A number of other institutional investors have also modified their holdings of PODD. Zions Bancorporation National Association UT bought a new stake in shares of Insulet during the first quarter valued at approximately $26,000. Larson Financial Group LLC increased its holdings in Insulet by 426.3% during the 1st quarter. Larson Financial Group LLC now owns 100 shares of the medical instruments supplier’s stock worth $26,000 after purchasing an additional 81 shares during the period. Golden State Wealth Management LLC raised its position in Insulet by 202.9% during the 2nd quarter. Golden State Wealth Management LLC now owns 103 shares of the medical instruments supplier’s stock valued at $32,000 after purchasing an additional 69 shares in the last quarter. SouthState Corp raised its position in Insulet by 253.3% during the 1st quarter. SouthState Corp now owns 106 shares of the medical instruments supplier’s stock valued at $28,000 after purchasing an additional 76 shares in the last quarter. Finally, Kozak & Associates Inc. purchased a new stake in shares of Insulet in the 2nd quarter worth $32,000.

Insider Buying and Selling at Insulet

In other news, SVP Prem Singh sold 687 shares of the company’s stock in a transaction on Monday, September 8th. The stock was sold at an average price of $347.49, for a total transaction of $238,725.63. Following the transaction, the senior vice president directly owned 3,456 shares of the company’s stock, valued at approximately $1,200,925.44. This represents a 16.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Laetitia Cousin sold 797 shares of the stock in a transaction on Monday, September 8th. The shares were sold at an average price of $348.81, for a total value of $278,001.57. Following the sale, the senior vice president owned 3,890 shares of the company’s stock, valued at approximately $1,356,870.90. This represents a 17.00% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.39% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

PODD has been the topic of several research reports. Stifel Nicolaus started coverage on Insulet in a research note on Tuesday, October 21st. They set a “buy” rating and a $370.00 price target on the stock. Piper Sandler upped their price objective on shares of Insulet from $320.00 to $360.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 16th. Zacks Research raised shares of Insulet from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, October 14th. Weiss Ratings restated a “hold (c)” rating on shares of Insulet in a report on Wednesday, October 8th. Finally, Royal Bank Of Canada increased their price objective on shares of Insulet from $365.00 to $370.00 and gave the company an “outperform” rating in a research note on Friday, November 7th. One investment analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $374.10.

Insulet Stock Performance

Shares of Insulet stock opened at $332.70 on Monday. The company has a market capitalization of $23.40 billion, a PE ratio of 101.12, a P/E/G ratio of 2.64 and a beta of 1.39. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.81 and a current ratio of 2.26. The company has a 50-day simple moving average of $323.58 and a two-hundred day simple moving average of $312.88. Insulet Corporation has a one year low of $230.05 and a one year high of $353.50.

Insulet (NASDAQ:PODD) last released its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 earnings per share for the quarter, beating analysts’ consensus estimates of $1.13 by $0.11. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The business had revenue of $521.70 million for the quarter, compared to analysts’ expectations of $678.70 million. During the same period last year, the business earned $1.08 EPS. The company’s revenue was up 29.9% compared to the same quarter last year. Insulet has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Research analysts expect that Insulet Corporation will post 3.92 EPS for the current fiscal year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.